Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new paper from the Heather and Tyler groups has uncovered the mechanism responsible for reduced energy in the hearts of patients with type 2 diabetes and revealed a new therapeutic strategy to reverse the energy deficit.

Graphical abstract showing increased energy levels in the heart when mitochondrial deacetylase SIRT3 activator "honokiol" is administered to the diabetic heart, compared to lower levels in the research control group.

Patients with type 2 diabetes have less energy within their hearts, resulting in less energy to power the pumping of the heart. However, the mechanisms responsible for this energy deficit, and whether therapies could be used to reverse this, have so far been unknown. 

The diabetic heart is a battery half empty - Prof Lisa Heather

New research led by Associate Professor Lisa Heather shows that early on in the development of diabetes, the cardiac mitochondria, known as the cellular power stations, work more slowly. This is due to a post-translational modification of a large number of mitochondrial enzymes. Mitochondrial proteins become hyperacetylated, which decreases the ability of the heart to use fuel for energy production. 

The team then demonstrate that a mitochondrial deacetylase SIRT3 activator, called honokiol, when administered in diabetes is able to reverse the hyperacetylation, speed up mitochondrial function and increase the amount of energy within the heart.

Prof Lisa Heather said: "By identifying the mechanisms and a way to reverse it, honokiol provides a therapeutic route to 'recharge the heart's battery' in diabetes."

"Ultimately, strategies to improve cardiac metabolism and energy generation in type 2 diabetes may provide much needed routes to decrease mortality from cardiovascular disease, the leading cause of death, in diabetes."

 

The full paper "Rescue of myocardial energetic dysfunction in diabetes through the correction of mitochondrial hyperacetylation by honokiol" is available to read in JCI Insight.

DPAG team members who have contributed to this paper include Matthew Kerr, Dr Jack Miller, Dr Kerstin Timm, Claudia Montes Aparicio and Professor Damian Tyler.

Similar stories

New research to radically alter our understanding of synaptic development

Publication Research

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Being "in the zone": how waking activity controls sleep need

Publication Research Vyazovskiy Group News

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.

New target identified to develop treatment for Abdominal Aortic Aneurysm

Cardiac Theme Publication Research

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

New research grant to Pawel Swietach to further understanding of propionic acidemia

Awards and Honours Cardiac Theme

A new collaborative project led by the Swietach group funded by the Propionic Acidemia Foundation will investigate the disease mechanisms and risk factors for cardiac disease caused by a severe inherited disorder.

Researcher publishes children's book of the brain

Postdoctoral Publication

Betina Ip, a Royal Society Dorothy Hodgkin Research Fellow based in NDCN, formerly a postdoctoral research scientist in DPAG, has written a book for children: The Usborne Book of the Brain and How it Works.